Alle Personen

Prof. Dr. Marylyn M. Addo

Weitere Beteiligungen

  • –   
    • Short Talk
    • S-2-3
    MVA-MERS-S vaccine candidate elicits long-lasting memory B cell response and highly potent cross-neutralizing antibodies against zoonotic merbecoviruses
     Immune Prevention and Therapy
    • Poster
    • P-1-79
    Intracellular mRNA:miRNA profiling after rVSV-ZEBOV vaccination
     Immune Prevention and Therapy
    • Poster
    • P-2-72
    Establishment of a multiplex digital PCR to detect MVA-based vaccines in human plasma
     Immune Prevention and Therapy
    • Poster
    • P-2-74
    Development of a preclinical model for human mpox disease using skin scarification in CAST/Eij
     Tropical and Emerging Infections
    • Poster
    • P-2-85
    Development of a live-attenuated monkeypox virus for use in improved diagnostics
     Tropical and Emerging Infections
    • Poster
    • P-2-104
    Mpox: evaluation of immune responses induced after infection versus vaccination
     Tropical and Emerging Infections
    • Poster
    • P-2-105
    MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike induce differential S1- and S2-specific immune responses in humans
     Tropical and Emerging Infections
    • Poster
    • P-1-78
    Dissecting humoral immune responses to the MVA-MERS-S vaccine candidate using a systems serology approach
     Immune Prevention and Therapy
  • –   
    • Short Talk
    • S-6-4
    The vaccine candidate MVA-MERS-S against Middle East Respiratory Syndrome Coronavirus: safety and immunogenicity results from a randomized-controlled Phase Ib trial
     Tropical and Emerging Infections
  • © Conventus Congressmanagement & Marketing GmbH